1 completed, 1 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow Molnupiravir 400 mg: new trials by email Literature Review of Molnupiravir 400 mg trials Research Report on Molnupiravir 400 mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adaptive Dengue Antiviral Platform Trial Molnupiravir 400 mg, VIS513 (a monoclonal antibody), Remdesivir 100mg - Dengue, Antiviral Drugs | Phase 2 | Recruiting | Oxford University Clinical Research Unit, Vietnam | 500 | 2026-04-20 | 2026-09-28 |
| Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19 Molnupiravir 200 mg, Molnupiravir 400 mg, Molnupiravir 800 mg - SARS-CoV-2 Infection, COVID-19 | Phase 2 | Completed | Ridgeback Biotherapeutics, LP | 204 | 2020-06-19 | 2022-02-16 |
Oxford University Clinical Research Unit, Vietnam (1) · Ridgeback Biotherapeutics, LP (1)
Malaysia (1) · United States (1) · Vietnam (1)